Since the last renewal, the previous Tissue Procurement Facility and Research Histology Shared Resource have merged and expanded their functions to form the Biorepository and Tissue Research Facility (BTRF), under new leadership. The BTRF makes human biospecimens available for basic, translational, and clinical research. It is the major conduit through which human tissue specimens are transferred from the Pathology, Surgery and other clinical departments to research labs at the University of Virginia (UVA), and is the major processor of human biospecimens (tissue, blood, urine) in support of clinical trials at UVA. In addition, this is the only shared research facility that supports standard histology services and complex histology-based analytic techniques for animal models and human tissues, including tissue microarray construction, laser microdissection, immunohistochemistry, digital slide scanning and reverse-phase protein microarrays. Expert histopathology support from Board-certified Anatomic Pathologists is provided for these activities through this Shared Resource. The biorepository and analytic services are often vertically integrated with each other to allow for """"""""one-stop shopping"""""""" for investigators carrying out translational or clinical cancer research. BTRF services make possible new insights into cancer disease mechanisms by the analysis of tissues and biofluids, assist in the discovery and validation of new clinical cancer biomarkers, and support clinical trials of novel diagnostic tests and therapies for cancer.
Analysis of human tissues is the conduit through which new knowledge about molecules and cells enters the realm of clinical practice. The BTRF provides both tissues and analytic tools to advance cancer diagnosis, prognosis, and treatment.
|Hao, Yi; Bjerke, Glen A; Pietrzak, Karolina et al. (2018) TGF? signaling limits lineage plasticity in prostate cancer. PLoS Genet 14:e1007409|
|Obeid, Joseph M; Kunk, Paul R; Zaydfudim, Victor M et al. (2018) Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time? Cancer Immunol Immunother 67:161-174|
|Wallrabe, Horst; Svindrych, Zdenek; Alam, Shagufta R et al. (2018) Segmented cell analyses to measure redox states of autofluorescent NAD(P)H, FAD & Trp in cancer cells by FLIM. Sci Rep 8:79|
|Olmez, Inan; Love, Shawn; Xiao, Aizhen et al. (2018) Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro Oncol 20:192-202|
|Wang, T Tiffany; Yang, Jun; Zhang, Yong et al. (2018) IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective ?-chain cytokines, decreases leukemic T-cell viability. Leukemia :|
|Yao, Nengliang; Zhu, Xi; Dow, Alan et al. (2018) An exploratory study of networks constructed using access data from an electronic health record. J Interprof Care :1-8|
|Kiran, Shashi; Dar, Ashraf; Singh, Samarendra K et al. (2018) The Deubiquitinase USP46 Is Essential for Proliferation and Tumor Growth of HPV-Transformed Cancers. Mol Cell 72:823-835.e5|
|Conaway, Mark R; Petroni, Gina R (2018) The Impact of Early-Phase Trial Design in the Drug Development Process. Clin Cancer Res :|
|Szlachta, Karol; Kuscu, Cem; Tufan, Turan et al. (2018) CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. Nat Commun 9:4275|
|Khalil, Shadi; Delehanty, Lorrie; Grado, Stephen et al. (2018) Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor. J Exp Med 215:661-679|
Showing the most recent 10 out of 539 publications